(Q37398588)

English

GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy

scientific article published on 20 September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy (English)

1 reference

Europe PubMed Central

20 August 2017

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Guru Sonpavde

1

1 reference

Europe PubMed Central

20 August 2017

Timothy C Thompson

2

1 reference

Europe PubMed Central

20 August 2017

Rajul K Jain

3

1 reference

Europe PubMed Central

20 August 2017

Gustavo E Ayala

4

1 reference

Europe PubMed Central

20 August 2017

Shinji Kurosaka

5

1 reference

Europe PubMed Central

20 August 2017

Kohei Edamura

6

1 reference

Europe PubMed Central

20 August 2017

Ken-ichi Tabata

7

1 reference

Europe PubMed Central

20 August 2017

Chengzhen Ren

8

1 reference

Europe PubMed Central

20 August 2017

Alexei A Goltsov

9

1 reference

Europe PubMed Central

20 August 2017

Martha P Mims

10

1 reference

Europe PubMed Central

20 August 2017

Teresa G Hayes

11

1 reference

Europe PubMed Central

20 August 2017

Michael M Ittmann

12

1 reference

Europe PubMed Central

20 August 2017

Thomas M Wheeler

13

1 reference

Europe PubMed Central

20 August 2017

Adrian Gee

14

1 reference

Europe PubMed Central

20 August 2017

Brian J Miles

15

1 reference

Europe PubMed Central

20 August 2017

Dov Kadmon

16

1 reference

Europe PubMed Central

20 August 2017

language of work or name

0 references

publication date

20 September 2011

1 reference

Europe PubMed Central

20 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

20 August 2017

17

1 reference

Europe PubMed Central

20 August 2017

7174-7182

1 reference

Europe PubMed Central

20 August 2017

22

1 reference

Europe PubMed Central

20 August 2017

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

6 September 2017

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

6 September 2017

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

6 September 2017

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

6 September 2017

Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

6 September 2017

Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

6 September 2017

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

6 September 2017

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

6 September 2017

Growth and survival mechanisms associated with perineural invasion in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

6 September 2017

RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

6 September 2017

mRTVP-1, a novel p53 target gene with proapoptotic activities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

6 September 2017

Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

6 September 2017

Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

14 September 2017

Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

2 September 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

2 September 2018

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

2 September 2018

Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

2 September 2018

Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

2 September 2018

Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

2 September 2018

Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

2 September 2018

Association of p53 mutations with metastatic prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865786

2 September 2018

A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21933889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/21933889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21933889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-11-1899

1 reference

Europe PubMed Central

20 August 2017

release_m6cy336a4jc6zboa7x24eshgjm

1 reference

https://api.fatcat.wiki/v0/release/m6cy336a4jc6zboa7x24eshgjm

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37398588&oldid=2093694805"